Northern Trust: PTC Therapeutics PTCT Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 56.2 M | Venta |
866,989
-13,040
| -1% | -USD 950 k | 0.01% | 1061 |
|
|
2026
Q2 | USD 71.8 M | Compra |
880,029
+73,753
| +9% | +USD 5.33 M | 0.01% | 987 |
|
|
2026
Q1 | USD 54.9 M | Compra |
806,276
+36,856
| +5% | +USD 2.61 M | 0.01% | 1045 |
|
|
2025
Q4 | USD 58.4 M | Compra |
769,420
+31,851
| +4% | +USD 2.31 M | 0.01% | 1016 |
|
|
2025
Q3 | USD 45.3 M | Venta |
737,569
-1,622
| -0.2% | -USD 84.5 k | 0.01% | 1201 |
|
|
2025
Q2 | USD 36.1 M | Venta |
739,191
-4,820
| -0.6% | -USD 229 k | 0.01% | 1294 |
|
|
2025
Q1 | USD 37.9 M | Compra |
744,011
+16,035
| +2% | +USD 800 k | 0.01% | 1256 |
|
|
2024
Q4 | USD 32.9 M | Compra |
727,976
+52,714
| +8% | +USD 2.26 M | ﹤0.01% | 1390 |
|
|
2024
Q3 | USD 25.1 M | Compra |
675,262
+16,803
| +3% | +USD 563 k | ﹤0.01% | 1478 |
|
|
2024
Q2 | USD 20.1 M | Venta |
658,459
-16,542
| -2% | -USD 536 k | ﹤0.01% | 1559 |
|
|
2024
Q1 | USD 19.6 M | Venta |
675,001
-13,846
| -2% | -USD 388 k | ﹤0.01% | 1608 |
|
|
2023
Q4 | USD 19 M | Venta |
688,847
-2,346
| -0.3% | -USD 53.6 k | ﹤0.01% | 1648 |
|
|
2023
Q3 | USD 15.5 M | Compra |
691,193
+5,061
| +0.7% | +USD 188 k | ﹤0.01% | 1718 |
|
|
2023
Q2 | USD 27.9 M | Compra |
686,132
+29,269
| +4% | +USD 1.43 M | 0.01% | 1371 |
|
|
2023
Q1 | USD 31.8 M | Compra |
656,863
+5,150
| +0.8% | +USD 235 k | 0.01% | 1240 |
|
|
2022
Q4 | USD 24.9 M | Compra |
651,713
+4,102
| +0.6% | +USD 171 k | 0.01% | 1403 |
|
|
2022
Q3 | USD 32.5 M | Venta |
647,611
-7,958
| -1% | -USD 390 k | 0.01% | 1141 |
|
|
2022
Q2 | USD 26.3 M | Venta |
655,569
-16,754
| -2% | -USD 587 k | 0.01% | 1350 |
|
|
2022
Q1 | USD 25.1 M | Venta |
672,323
-36,300
| -5% | -USD 1.4 M | ﹤0.01% | 1516 |
|
|
2021
Q4 | USD 28.2 M | Venta |
708,623
-5,758
| -0.8% | -USD 220 k | ﹤0.01% | 1532 |
|
|
2021
Q3 | USD 26.6 M | Venta |
714,381
-21,105
| -3% | -USD 867 k | ﹤0.01% | 1589 |
|
|
2021
Q2 | USD 31.1 M | Compra |
735,486
+5,568
| +0.8% | +USD 239 k | 0.01% | 1563 |
|
|
2021
Q1 | USD 34.6 M | Venta |
729,918
-48,389
| -6% | -USD 2.87 M | 0.01% | 1422 |
|
|
2020
Q4 | USD 47.5 M | Venta |
778,307
-23,290
| -3% | -USD 1.37 M | 0.01% | 1115 |
|
|
2020
Q3 | USD 37.5 M | Venta |
801,597
-37,747
| -4% | -USD 1.86 M | 0.01% | 1116 |
|
|
2020
Q2 | USD 42.6 M | Compra |
839,344
+54,583
| +7% | +USD 2.68 M | 0.01% | 1012 |
|
|
2020
Q1 | USD 35 M | Compra |
784,761
+19,015
| +2% | +USD 957 k | 0.01% | 1008 |
|
|
2019
Q4 | USD 36.8 M | Compra |
765,746
+8,720
| +1% | +USD 371 k | 0.01% | 1237 |
|
|
2019
Q3 | USD 25.6 M | Compra |
757,026
+74,794
| +11% | +USD 3.26 M | 0.01% | 1482 |
|
|
2019
Q2 | USD 30.7 M | Compra |
682,232
+12,454
| +2% | +USD 492 k | 0.01% | 1373 |
|
|
2019
Q1 | USD 25.2 M | Compra |
669,778
+79,551
| +13% | +USD 2.67 M | 0.01% | 1488 |
|
|
2018
Q4 | USD 20.3 M | Venta |
590,227
-172,111
| -23% | -USD 6.19 M | 0.01% | 1573 |
|
|
2018
Q3 | USD 35.8 M | Compra |
762,338
+25,446
| +3% | +USD 1.05 M | 0.01% | 1299 |
|
|
2018
Q2 | USD 24.9 M | Compra |
736,892
+71,756
| +11% | +USD 2.24 M | 0.01% | 1598 |
|
|
2018
Q1 | USD 18 M | Venta |
665,136
-2,521
| -0.4% | -USD 63.9 k | ﹤0.01% | 1765 |
|
|
2017
Q4 | USD 11.1 M | Venta |
667,657
-9,573
| -1% | -USD 162 k | ﹤0.01% | 2118 |
|
|
2017
Q3 | USD 13.6 M | Compra |
677,230
+62,134
| +10% | +USD 1.22 M | ﹤0.01% | 2003 |
|
|
2017
Q2 | USD 11.3 M | Compra |
615,096
+48,308
| +9% | +USD 651 k | ﹤0.01% | 2090 |
|
|
2017
Q1 | USD 5.58 M | Compra |
566,788
+3,231
| +0.6% | +USD 39.1 k | ﹤0.01% | 2490 |
|
|
2016
Q4 | USD 6.15 M | Compra |
563,557
+16,489
| +3% | +USD 173 k | ﹤0.01% | 2414 |
|
|
2016
Q3 | USD 7.66 M | Compra |
547,068
+90,461
| +20% | +USD 735 k | ﹤0.01% | 2237 |
|
|
2016
Q2 | USD 3.2 M | Compra |
456,607
+54,073
| +13% | +USD 397 k | ﹤0.01% | 2753 |
|
|
2016
Q1 | USD 3.06 M | Venta |
402,534
-25,470
| -6% | -USD 442 k | ﹤0.01% | 2735 |
|
|
2015
Q4 | USD 13.9 M | Compra |
428,004
+8,295
| +2% | +USD 244 k | ﹤0.01% | 1765 |
|
|
2015
Q3 | USD 11.2 M | Compra |
419,709
+81,235
| +24% | +USD 3.47 M | ﹤0.01% | 1919 |
|
|
2015
Q2 | USD 16.3 M | Compra |
338,474
+35,370
| +12% | +USD 2.06 M | ﹤0.01% | 1746 |
|
|
2015
Q1 | USD 18.4 M | Compra |
303,104
+16,959
| +6% | +USD 1.03 M | 0.01% | 1644 |
|
|
2014
Q4 | USD 14.8 M | Compra |
286,145
+22,768
| +9% | +USD 1 M | ﹤0.01% | 1766 |
|
|
2014
Q3 | USD 11.6 M | Compra |
263,377
+104,813
| +66% | +USD 3.28 M | ﹤0.01% | 1927 |
|
|
2014
Q2 | USD 4.14 M | Compra |
158,564
+8,554
| +6% | +USD 183 k | ﹤0.01% | 2649 |
|
|
2014
Q1 | USD 3.92 M | Compra |
150,010
+18,488
| +14% | +USD 497 k | ﹤0.01% | 2709 |
|
|
2013
Q4 | USD 2.23 M | Compra |
131,522
+87,136
| +196% | +USD 1.53 M | ﹤0.01% | 3087 |
|
|
2013
Q3 | USD 953 k | Compra |
+44,386
| Nuevas | +USD 771 k | ﹤0.01% | 3346 |
|
Otros fondos que tienen PTCT en su portafolio
Posición de Northern Trust en PTCT: resumen de T3 2026
Northern Trust redujo su participación en PTC Therapeutics (PTCT) en 1.5% durante T3 2026, al vender acciones por un valor estimado de USD 950 k y quedarse con 866,989 acciones valuadas en USD 56.2 M. La posición representa 0.01% del portafolio y ocupa el puesto #1061.
Northern Trust reportó por primera vez una posición en PTCT en T3 2013 y desde entonces la ha mantenido en 53 trimestres. La posición alcanzó su máximo de USD 71.8 M en T2 2026. Al cierre de T3 2026, 361 fondos que sigue Wall St. Rank mantienen una posición en PTCT.
- Al cierre de T3 2026, Northern Trust tenía 866,989 acciones de PTC Therapeutics con un valor de USD 56.2 M.
- Northern Trust vendió 13,040 acciones de PTC Therapeutics en T3 2026, por un valor estimado de USD 950 k.
- PTC Therapeutics representó el 0.01% del portafolio de Northern Trust en T3 2026 y fue su posición número 1061.
- Northern Trust reportó por primera vez una posición en PTC Therapeutics en T3 2013 y desde entonces la ha mantenido en 53 trimestres.
- La posición de Northern Trust en PTC Therapeutics alcanzó su máximo de USD 71.8 M en T2 2026.
- Al cierre de T3 2026, 361 fondos que sigue Wall St. Rank tenían PTC Therapeutics en su portafolio.
Según el informe 13F de Northern Trust correspondiente a T3 2026, presentado el 16 nov 2026.